TARGET THERAPY IN PATIENTS OF LIVER METASTATIC CANCER PATIENTS IN REAL CLINICAL PRACTICE

Abstract

Information about retraction of an articleAnalysis conducted by the members of the editorial board has revealed the direct borrowing without reference to the specific source of citations in the following articles:The article by Alekseev B.Ya., Nyushko K.M., Kalpinskiy A.S. Targeted therapy in patients with metastatic kidney cancer in real clinical practice and the article by Alekseev B.Ya., Nyushko K.M., Kalpinskiy A.S. The use of sunitinib in real clinical practice in patients with metastatic kidney cancer // Onkourologiya = Oncourology – 2016 – V. 12 - No. 1 – p. 14-20.Based on the decision of the Editorial Board of the journal Medical Council dated January 17, 2020, the following article has been retracted:Alekseev B.Ya., Nyushko K.M., Kalpinskiy A.S. Targeted therapy in patients with metastatic kidney cancer in real clinical practice // Meditsinskiy sovet - Medical Council – 2016 – 10 – p. 48-55.The article presents the findings of clinical studies with use of sunitinib with advanced inclusion criteria and of non-randomized studies in which sunitinib clinical effectiveness is proved in patients with unfavorable forecast of the therapy course, non clearcell variants of mRCC, metastases in the brain, in elderly patients and in patients at the terminal stage of the renal insufficiency requiring hemodialysis. Despite lower values of objective response frequency, the survival rate without progressing in this category of patients as compared to patients with small-cell mRCC was comparable and the total survival rate was a little lower than in the registration randomized clinical study.

Keywords

• metastatic small-cell cancer
• target therapy
• tyrosine kinase inhibitors
• sunitinib